**Exhibit99.1**
| Angeion Corporation       |   |
|---------------------------|--------|
| 350 Oak Grove Parkway     |   |
| St. Paul, MN 55127 USA    |        |
| Telephone: (651) 484-4874 |
| Facsimile: (651) 484-4826 |
|                      |

 

**FOR IMMEDIATE RELEASE**

Contact:                  RodneyA. Young, President and Chief Executive Officer, (651) 484-4874

Dale H. Johnson, ChiefFinancial Officer, (651) 484-4874

***Angeion Corporation Reports***

***Continued Strong Results in Second Quarter of 2007***

**SAINT PAUL, Minnesota. (June 5, 2007)**— Angeion Corporation (NASDAQ: ANGN)today reported results for its second quarter ended April 30, 2007.

“We saw acontinuation of positive performance at Angeion in the second quarter,” RodneyA. Young, President and Chief Executive Officer commented.  “Once again we achieved strong year-over-yearrevenue growth in each of our three principal markets—hospitals and physicianoffices, clinical research, and health and fitness.”

**Growthand Progress in the Second Quarter**

Notableaccomplishments for the quarter included:

·                  38% growth inrevenue over the second quarter of 2006

·                  Double-digityear-over-year revenue growth for the twelfth consecutive quarter

·                  Seventhconsecutive quarter of profitability

·                  Gross margin of50.5% versus 48.9% in second quarter of 2006

·                  120% increase innet income over the second quarter of 2006.

Angeion reportednet income of $453,000, or $0.11 per diluted share, on revenue of $10.0 millionin the second quarter of 2007.  Thiscompares to net income of $206,000, or $0.05 per diluted share, on revenue of$7.2 million in the second quarter of 2006. Net income in the second quarter of 2006 included a gain fromdiscontinued operations of $175,000 or $0.04 per diluted share.

— More —

1

----

For the six monthsended April 30, 2007, Angeion reported net income of $942,000, or $0.22 perdiluted share, on revenue of $20.6 million. This compares to net income of $288,000, or $0.08 per diluted share, onrevenue of $14.1 million for the same period of 2006.  Net income for the six months ended April 30,2006, included a gain from discontinued operations of $171,000 or $0.05 perdiluted share.

“Sales of ourMedGraphics products to hospitals, clinics and physicians offices as well as toclinical research customers continued to be strong, particularly in theinternational markets,” Young said.  “Itis notable that MedGraphics cardiorespiratory diagnostic product revenues inthe quarter grew by 20.5% over the second quarter of last year, even withoutthe contribution of clinical research sales. Additionally, unit sales of Client Assessment Packs, an indicator of newconsumer participation in the New Leaf Active Metabolic TrainingTM programs,increased 56% in the second quarter compared to the same period of 2006.  For New Leaf, year-to-date unit sales havegrown 54% over the first six months of our last fiscal year.  Demand for our products in all our marketscontributed to our twelfth consecutive quarter of double-digit revenue growthand seventh consecutive quarter of profitability.”

The Company alsonoted two important events in the quarter—the opening of a Medical GraphicsEuropean branch office in Milan, Italy, and an agreement with GarminInternational enabling integration of Angeion’s New Leaf Active Metabolictraining with Garmin’s Forerunner® 305 GPS fitness device that utilizes the internetfor the delivery of online programs and services to health and fitnessprofessionals, health club partners and consumers.

**LookingAhead**

“The first half of 2007 has been the best ever in ourCompany.  As we look forward, there areseveral market drivers that give us great confidence that the demand for our “breathby breath” cardiopulmonarytechnology will continue to grow.  Thesemarket drivers include:

·                  an increasing number of cardiopulmonarydiagnostic procedures in hospitals moving to physician offices,

·                  technologyadvancements such as internet applications,

·                  therole of cardiopulmonary non-invasive diagnostics expanding as pre-surgical evaluations to reducemorbidity and mortally,

·                  the growingnumber of pharmaceutical and medical device research and development clinicalstudies specific to the lungs or heart which require safety and efficacy validation,

2

----

·                  increasingapplication for our cardiopulmonarytechnology as a predictor of heart failure outcomes and a diagnostic tool fordisease prevention and treatment,

·                  demographictrends for obesity, aging population and cardiopulmonary disease drivingincreased procedure reimbursement for use of our products.”

## “Weexpect strong year-end contributions from all areas of our business, with solidrevenue from our MedGraphics hospital and physician office customers, ourclinical research customers, and our New Leaf customers.  Revenue from our largest clinical researchcustomer will continue in fiscal 2007, but at a reduced level due to the wind downof the systems installation phase of its current clinical studies.  This will affect our overall third and fourthquarter 2007 revenues and our profitability as compared with the same periodsin 2006.  We expect to remain profitablein the second half of the year, however, and to report double-digit revenuegrowth for the year as whole.  We furtherexpect to report increased year-over-year revenues in the second half of 2007from both our MedGraphics hospital and physician office customers and our New Leafcustomers.  In addition, we continue topursue a number of additional opportunities with our clinical research studycustomers to expand our future growth outside of sales to our traditionalMedGraphics hospital and physician office customers and our New Leaf customers,”Young commented.

“For the remainderof 2007, we are continuing our focus on the following initiatives:

·                  expand ourinternational distribution and partnerships,

·                  drive sales intothe growing physician office and clinic markets,

·                  maintain ourindustry-leading customer service and technical support,

·                  continue to gainnew clinical research clients,

·                  grow our numberof New Leaf health and fitness delivery sites,

·                  drive moremetabolic assessments, as well as

·                  introducenew products and services to expand the breadth and depth of Angeion’sportfolio,” Young concluded.

3

----

**About Angeion Corporation**

Founded in 1986, Angeion Corporation acquired Medical GraphicsCorporation in December 1999.  MedicalGraphics develops, manufactures and markets non-invasive cardiorespiratorydiagnostic systems that are sold under the MedGraphics (www.medgraphics.com)and New Leaf (www.newleaffitness.com) brand and trade names.  These cardiorespiratory diagnostic systemshave a wide range of applications in healthcare as well as health andfitness.  The Company’s products are soldinternationally through distributors and in the United States through a directsales force that targets heart and lung specialists located in hospitals,university-based medical centers, medical clinics and physicians’ offices,pharmaceutical companies, medical device manufacturers, clinical researchorganizations, health and fitness clubs, personal training studios, and otherexercise facilities.  For moreinformation about Angeion, visit www.angeion.com.

 

The discussion above contains forward-lookingstatements within the meaning of the Private Securities Litigation Reform Actof 1995.  These statements by theirnature involve substantial risks and uncertainties.  Our results may differ materially dependingon a variety of factors, including: (i) our ability to successfully operate ourbusiness, including our ability to develop, improve, and update ourcardiorespiratory diagnostic products, (ii) our ability to achieve constantmargins for products and consistent and predictable operating expenses in lightof fluctuating revenues from our clinical research customers, (iii) our abilityto effectively manufacture and ship our products in required quantities to meetcustomer demands, (iv) our ability to successfully defend the Company fromproduct liability claims related to our cardiorespiratory diagnostic productsand claims associated with our prior cardiac stimulation products, (v) ourability to protect our intellectual property, (vi) our ability to develop andmaintain an effective system of internal controls and procedures and disclosurecontrols and procedures, and (vii) our dependence on third-party vendors.  Additional information with respect to therisks and uncertainties faced by the Company may be found in, and any priordiscussion is qualified in its entirety by, the other risk factors that aredescribed from time to time in Angeion’s Securities and Exchange Commissionreports, including but not limited to the Annual Report on Form 10-KSB for theyear ended October 31, 2006, and subsequently filed reports.

— FinancialsFollow —

4

----

**ANGEION CORPORATION AND SUBSIDIARIES**

**Condensed Consolidated Statements of Earnings**

(unaudited,in thousands except per share amounts)

 
| ** **                                               | ** ** | **Three Months Ended** | ** ** | **Six Months Ended** | ** ** |
|----------------------------------------------------------|------------|----------------------------------|------------|--------------------------------|------------|
| ** **                                               | ** ** | **April 30,**               | ** ** | **April 30,**             | ** ** |
| **Consolidated Statements of Earnings**   | ** ** | **2007**                         | ** ** | **2006**                       | ** ** | **2007** | ** ** | **2006** | ** ** |
| Revenues                                                 |       | $                                | 9,960      |                           | $          | 7,212 |   | $ | 20,579 |   | $ | 14,145 |   |
| Cost of goods sold                                       |       | 4,934                            |       | 3,683                          |       | 10,266 |   | 7,087 |   |
| Gross margin                                             |       | 5,026                            |       | 3,529                          |       | 10,313 |   | 7,058 |   |
|                                                     |       |                             |       |                           |       |   |   |   |   |
| Operating expenses:                                      |       |                             |       |                           |       |   |   |   |   |
| Selling and  marketing                                   |       | 2,536                            |       | 1,852                          |       | 5,011 |   | 3,805 |   |
| General and  administrative                              |       | 887                              |       | 806                            |       | 2,047 |   | 1,519 |   |
| Research and  development                                |       | 693                              |       | 571                            |       | 1,368 |   | 1,054 |   |
| Amortization of  intangibles                             |       | 190                              |       | 203                            |       | 385 |   | 406 |   |
|                                                     |       | 4,306                            |       | 3,432                          |       | 8,811 |   | 6,784 |   |
| Operating income                                         |       | 720                              |       | 97                             |       | 1,502 |   | 274 |   |
| Interest income                                          |       | 47                               |       | 19                             |       | 83 |   | 28 |   |
| Income before taxes                                      |       | 767                              |       | 116                            |       | 1,585 |   | 302 |   |
| Provision for  taxes                                     |       | 314                              |       | 85                             |       | 643 |   | 185 |   |
|                                                     |       |                             |       |                           |       |   |   |   |   |
| Income from continuing  operations                       |       | 453                              |       | 31                             |       | 942 |   | 117 |   |
| Gain from discontinued operations,  net of $103 of taxes |       | —                           |       | 175                            |       | — |   | 171 |   |
| Net income                                               |       | $                                | 453        |                           | $          | 206 |   | $ | 942 |   | $ | 288 |   |
|                                                     |       |                             |       |                           |       |   |   |   |   |
| Earnings per share -  basic                              |       |                             |       |                           |       |   |   |   |   |
| Continuing  operations                                   |       | $                                | 0.11       |                           | $          | 0.01 |   | $ | 0.24 |   | $ | 0.03 |   |
| Discontinued  operations                                 |       | —                           |       | 0.05                           |       | — |   | 0.05 |   |
| Net income per  share                                    |       | $                                | 0.11       |                           | $          | 0.06 |   | $ | 0.24 |   | $ | 0.08 |   |
| Earnings per share -  diluted                            |       |                             |       |                           |       |   |   |   |   |
| Continuing  operations                                   |       | $                                | 0.11       |                           | $          | 0.01 |   | $ | 0.22 |   | $ | 0.03 |   |
| Discontinued  operations                                 |       | —                           |       | 0.04                           |       | — |   | 0.05 |   |
| Net income per  share                                    |       | $                                | 0.11       |                           | $          | 0.05 |   | $ | 0.22 |   | $ | 0.08 |   |
| Weighted average common  shares outstanding              |       |                             |       |                           |       |   |   |   |   |
| Basic                                                    |       | 3,945                            |       | 3,619                          |       | 3,890 |   | 3,615 |   |
| Diluted                                                  |       | 4,310                            |       | 3,760                          |       | 4,279 |   | 3,714 |   |

 
| ** **                                | ** ** | **April 30** | ** ** | **October 31,** | ** ** |
|-------------------------------------------|------------|-------------------|------------|----------------------|------------|
| **Consolidated Balance Sheets** | ** ** | **2007**          | ** ** | **2006**             | ** ** |
| Cash                                      |       | $                 | 4,386      |                 | $          | 4,069 |   |
| Other current assets                      |       | 14,787            |       | 12,821               |       |
| Equipment and  intangible assets          |       | 4,002             |       | 4,863                |       |
|                                      |       | $                 | 23,175     |                 | $          | 21,753 |   |
|                                      |       |              |       |                 |       |
| Current liabilities                       |       | 5,731             |       | 6,686                |       |
| Long-term liabilities                     |       | 647               |       | 757                  |       |
| Shareholders’ equity                 |       | 16,797            |       | 14,310               |       |
|                                      |       | $                 | 23,175     |                 | $          | 21,753 |   |

 

###

5

----